Multi-intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in Heart Failure With Reduced Ejection Fraction（PRIME-HFrEF Study）

Summary

This study is an exploratory clinical study to observe the safety and efficacy of the Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells in the heart failure patients with reduced ejection fraction. The study was a 12 months single center, randomized, double-blind, placebo-controlled trial that included 12 weeks of treatment, and 9 months of follow-up.

Timeline

Start

2021-07-28

Primary completion

2023-01-17

Completion

2023-04-04

Publications

• Han W, Jiao Y, Chen W, Gong X, Hu H, Xin Y, Guan S, Zhao J, Zhang Q, Yang B, Pan J, Wang H, Lu Q, Chu S, Cai D, Zheng L, Jia W, He Z, Yang H, Sun YE, Liu Z. PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure. Signal Transduct Target Ther. 2026 Mar 26;11(1):112. doi: 10.1038/s41392-026-02678-5.

Drugs

Indications